Kymriah was the first approved CAR-T cell product (CD19/FMC63) by FDA on August 31, 2017 indicated, for the treatment of patients (below 25 years of age) with B-cell precursor acute lymphoblastic leukemia (B-ALL) that was in refractory or in second or later relapse [18]. Here, CD19 is linked to acute lymphoblastic leukemia.